# Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery

> **NCT00700882** · PHASE2 · COMPLETED · sponsor: **Eastern Cooperative Oncology Group** · enrollment: 81 (actual)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **DRUG:** dasatinib

## Key facts

- **NCT ID:** NCT00700882
- **Lead sponsor:** Eastern Cooperative Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07-02
- **Primary completion:** 2016-05-06
- **Final completion:** 2020-12-28
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2023-07-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00700882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00700882, "Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00700882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*